Connect with us

Company News

Zydus Receives Tentative Approval from the USFDA for Deferasirox Tablets

Zydus Cadila has received the tentative approval from the USFDA to market Deferasirox Tablets, 90 mg, 180 mg, and 360 mg (US RLD – Exjade Tablets). It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. It is used to treat ongoing high levels of iron in the body caused by multiple blood transfusions. It is also used to treat high levels of iron in people with a certain blood disorder who do not require blood transfusions (non-transfusion-dependent thalassemia). The group now has 231 approvals and has so far filed over 340 ANDAs since the commencement of the filing process in FY 2003-04. – Medical Buyer Bureau

Copyright © 2024 Medical Buyer

error: Content is protected !!